Pakistan vs Sao Tome and Principe: Immunization, Hib3
Pakistan
87.0%
in 2024
Sao Tome and Principe
87.0%
in 2024
Pakistan rank
117th
Sao Tome and Principe rank
117th
Immunization, Hib3 over time
- Pakistan
- Sao Tome and Principe
How they compare
Pakistan currently reports 87.0% against 87.0% in Sao Tome and Principe, a difference of 0.0%.
Across all 15 years both countries report, Sao Tome and Principe has been ahead every year.
Pakistan ranks 117th and Sao Tome and Principe ranks 117th of 191 countries.
Sao Tome and Principe has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Pakistan | Sao Tome and Principe | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 69.9% | 95.9% | 26.0% | Sao Tome and Principe |
| 2020s | 84.2% | 91.8% | 7.6% | Sao Tome and Principe |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hib3, Pakistan or Sao Tome and Principe?
- Pakistan, at 87.0% against 87.0% in Sao Tome and Principe as of 2024.
- What is the difference in immunization, hib3 between Pakistan and Sao Tome and Principe?
- 0.0%, with Pakistan ahead.
- How many years of comparable data are there for Pakistan and Sao Tome and Principe?
- 15 years are reported by both, from 2010 to 2024.
- How do Pakistan and Sao Tome and Principe rank globally for immunization, hib3?
- Pakistan ranks 117th and Sao Tome and Principe ranks 117th of 191 countries.
- Where does this data come from?
- WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as Immunization, Hib3 (% of children ages 12-23 months). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.